Explore the latest in stem cell transplantation, including recent advances in indications for the procedure, safer conditioning regimens, and more.
In this randomized trial, nonmyeloablative hematopoietic stem cell transplantation (HSCT) resulted in longer time to disease progression among patients with relapsing-remitting multiple sclerosis compared with continued disease-modifying therapy.
This cohort study examines cause-specific late mortality among individuals who have lived 2 years or more after allogeneic blood or marrow transplantation performed in childhood and whether rates of late mortality have changed over time.
This cohort study examines patient data in the European Society for Blood and Marrow Transplantation Registry for causes of death, risk factors, and overall survival rates among patients who received a second cancer diagnosis after being treated with stem cell transplant.
This case report describes alopecia universalis and chronic graft-vs-host disease occurring after allogenic hematopoietic stem-cell transplantation and treated with ruxolitinib.
This Medical News & Perspectives article examines the proliferation of US clinics offering unproven stem cell therapies.
This open-label randomized clinical trial involving pediatric patients with acute leukemia receiving intensive chemotherapy or undergoing hematopoietic stem cell transplantation compares the rate of bacteremia among those who received levofloxacin prophylaxis with those who did not.
This registry-based study compares survival in patients with acute myelogenous leukemia who have undergone a second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion after relapse.
This case series examines the factors that contribute to disease progression and neurological deterioration in children who undergo hematopoietic stem cell transplantation to treat cerebral X-linked adrenoleukodystrophy.
This case series describes the occurrence of graft-vs-host-disease (GVHD) in patients with cutaneous T-cell lymphomas (CTCLs) treated with the CC chemokine receptor 4 (CCR4) antibody mogalizumab prior to allogeneic hematopoietic stem cell transplantation (HSCT).
This study examines crowdfunding campaigns on GoFundMe and YouCaring sponsored by US-based businesses engaging in direct-to-consumer marketing of stem cell interventions to discover whether the benefits and risks are mentioned in the campaign descriptions.
This systematic review and meta-analysis reviews phase 3 randomized clinical trials of high-dose therapy followed by autologous stem cell transplant in patients with multiple myeloma.
This cohort study examines the prognostic association of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia and a risk-stratifying composite model that incorporates comorbidities, age, and cytogenetic/molecular risks.
A 66-year-old man developed noninfectious fever and rash after autologous HSCT. Chest computed tomography showed ground-glass and consolidative lung opacities; skin punch biopsy showed vacuolar change and superficial perivascular mononuclear cell infiltrate. What would you do next?
This study used a telephone survey to assess the type of treatment, cost, and statements made about efficacy at unregulated stem cell centers.
A 35-year-old woman with a history of hypertension and chronic lymphocytic leukemia who underwent allogenic bone marrow transplant presents to an emergency department with shortness of breath and productive cough. What would you do next?
This clinical trial, which was stopped early, seeks to evaluate whether the early administration of azithromycin would improve airflow decline–free survival among patients who had undergone an allogeneic hematopoietic stem cell transplant.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: